|Bid||107.33 x 900|
|Ask||107.99 x 1000|
|Day's Range||107.04 - 108.62|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||28.95|
|Earnings Date||Oct 28, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||5.20 (4.86%)|
|Ex-Dividend Date||Oct 14, 2021|
|1y Target Est||127.01|
AbbVie Inc said on Tuesday the U.S. health regulator approved its once-daily oral medicine for preventive treatment of migraine in adults, adding a third drug to the drugmaker's arsenal of therapies for severe headaches. The drug, Qulipta, which AbbVie will launch in early October, will enter a crowded market for migraine prevention drugs such as Eli Lilly's Emgality, Amgen Inc's Aimovig and Biohaven Pharmaceutical Holding Co Ltd's Nurtec ODT. AbbVie acquired Qulipta in 2020 as part of its $63 billion deal for Allergan, along with anti-wrinkle and chronic migraine treatment Botox and acute migraine drug Ubrelvy.
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.2
Investors looking to their investments for current and future income should think critically about the nature of a company's business.